Top

Published in:

01-12-2014 | Review

Bioinformatics for cancer immunotherapy target discovery

Authors: Lars Rønn Olsen, Benito Campos, Mike Stein Barnkob, Ole Winther, Vladimir Brusic, Mads Hald Andersen

Published in: Cancer Immunology, Immunotherapy | Issue 12/2014

Abstract

The mechanisms of immune response to cancer have been studied extensively and great effort has been invested into harnessing the therapeutic potential of the immune system. Immunotherapies have seen significant advances in the past 20 years, but the full potential of protective and therapeutic cancer immunotherapies has yet to be fulfilled. The insufficient efficacy of existing treatments can be attributed to a number of biological and technical issues. In this review, we detail the current limitations of immunotherapy target selection and design, and review computational methods to streamline therapy target discovery in a bioinformatics analysis pipeline. We describe specialized bioinformatics tools and databases for three main bottlenecks in immunotherapy target discovery: the cataloging of potentially antigenic proteins, the identification of potential HLA binders, and the selection epitopes and co-targets for single-epitope and multi-epitope strategies. We provide examples of application to the well-known tumor antigen HER2 and suggest bioinformatics methods to ameliorate therapy resistance and ensure efficient and lasting control of tumors.

Kirkwood JM, Butterfield LH, Tarhini AA et al (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62:309–335. doi:10.3322/caac.20132 PubMedCentralPubMed

Rees R, Laversin S, Murray C, Ball G (2012) Current approaches to identify and evaluate cancer biomarkers for patient stratification. In: Morrow WJW, Sheikh NA, Schmidt CS, Davies DH (eds) Vaccinology: principles and Practice. Wiley, Oxford, pp 452–463

Wei W-Z, Morris GP, Kong Y-CM (2004) Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73–78. doi:10.1007/s00262-003-0444-1 PubMed

Blades RA, Keating PJ, McWilliam LJ et al (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681–686. doi:10.1016/S0090-4295(99)80301-X (discussion 686–7)PubMed

Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949. doi:10.1038/nm1093 PubMed

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506 PubMedCentralPubMed

Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27:3889–3900. doi:10.1038/onc.2008.35 PubMed

Bronte V, Serafini P, De Santo C et al (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 170:270–278PubMed

Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52PubMed

10.

Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54. doi:10.1038/nm976 PubMed

11.

Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268. doi:10.1038/85330 PubMed

12.

Falk K, Rötzschke O, Stevanović S et al (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290–296. doi:10.1038/351290a0 PubMed

13.

Reinherz EL, Tan K, Tang L et al (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913–1921PubMed

14.

Rock KL, Gramm C, Rothstein L et al (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761–771PubMed

15.

Androlewicz MJ, Anderson KS, Cresswell P (1993) Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc Natl Acad Sci USA 90:9130–9134PubMedCentralPubMed

16.

Henney CS, Gaffney J, Bloom BR (1974) On the relation of products of activated lymphocytes to cell-mediated cytolysis. J Exp Med 140:837–852PubMedCentralPubMed

17.

Van der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647. doi:10.1126/science.1840703 PubMed

18.

Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729PubMed

19.

Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693PubMed

20.

Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337. doi:10.1158/1078-0432.CCR-09-0737 PubMed

21.

Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207. doi:10.1007/s00262-004-0560-6 PubMed

22.

Seremet T, Brasseur F, Coulie PG (2011) Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 17:325–330. doi:10.1097/PPO.0b013e3182326004 PubMed

23.

Lurquin C, Van Pel A, Mariamé B et al (1989) Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293–303PubMed

24.

Mariuzza RA, Phillips SE, Poljak RJ (1987) The structural basis of antigen-antibody recognition. Annu Rev Biophys Biophys Chem 16:139–159. doi:10.1146/annurev.bb.16.060187.001035 PubMed

25.

Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998. doi:10.1038/ni1102-991 PubMed

26.

Rappuoli R (2000) Reverse vaccinology. Curr Opin Microbiol 3:445–450PubMed

27.

Harndahl M, Rasmussen M, Roder G et al (2012) Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 42:1405–1416. doi:10.1002/eji.201141774 PubMed

28.

Rudolph MG, Stanfield RL, Wilson IA (2006) How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24:419–466. doi:10.1146/annurev.immunol.23.021704.115658 PubMed

29.

Dhanasekaran SM, Barrette TR, Ghosh D et al (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826. doi:10.1038/35090585 PubMed

30.

Spentzos D, Levine DA, Ramoni MF et al (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22:4700–4710. doi:10.1200/JCO.2004.04.070 PubMed

31.

Buyse M, Loi S, van’t Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192. doi:10.1093/jnci/djj329 PubMed

32.

Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020 PubMedCentralPubMed

33.

Snuderl M, Fazlollahi L, Le LP et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810–817. doi:10.1016/j.ccr.2011.11.005 PubMed

34.

Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014. doi:10.1073/pnas.1219747110 PubMedCentralPubMed

35.

Campoli M, Chang C-C, Ferrone S (2002) HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 20(Suppl 4):A40–A45PubMed

36.

Chang C-C, Campoli M, Restifo NP et al (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462–1471PubMedCentralPubMed

37.

Sioud M, Hansen M, Dybwad A (2000) Profiling the immune responses in patient sera with peptide and cDNA display libraries. Int J Mol Med 6:123–128PubMed

38.

Hanash S (2003) Disease proteomics. Nature 422:226–232. doi:10.1038/nature01514 PubMed

39.

Loging WT, Lal A, Siu IM et al (2000) Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 10:1393–1402PubMedCentralPubMed

40.

Scanlan MJ, Gordon CM, Williamson B et al (2002) Identification of cancer/testis genes by database mining and mRNA expression analysis. Int J Cancer 98:485–492PubMed

41.

Ramsay G (1998) DNA chips: state-of-the art. Nat Biotechnol 16:40–44. doi:10.1038/nbt0198-40 PubMed

42.

Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10:57–63. doi:10.1038/nrg2484 PubMedCentralPubMed

43.

Gentleman RC, Carey VJ, Bates DM et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80. doi:10.1186/gb-2004-5-10-r80 PubMedCentralPubMed

44.

Irizarry RA, Hobbs B, Collin F et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264. doi:10.1093/biostatistics/4.2.249 PubMed

45.

Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3. doi: 10.2202/1544-6115.1027

46.

Perez-Llamas C, Lopez-Bigas N (2011) Gitools: analysis and visualisation of genomic data using interactive heat-maps. PLoS ONE 6:e19541. doi:10.1371/journal.pone.0019541 PubMedCentralPubMed

47.

Chatterjee M, Draghici S, Tainsky MA (2006) Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr Opin Drug Discov Dev 9:380–385

48.

Miller JC, Zhou H, Kwekel J et al (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3:56–63. doi:10.1002/pmic.200390009 PubMed

49.

Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452:571–579. doi:10.1038/nature06916 PubMed

50.

Bendall SC, Simonds EF, Qiu P et al (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332:687–696. doi:10.1126/science.1198704 PubMedCentralPubMed

51.

Imielinski M, Cha S, Rejtar T et al (2012) Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteomics 11(M111):014910. doi:10.1074/mcp.M111.014910 PubMed

52.

Nilsson T, Mann M, Aebersold R et al (2010) Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 7:681–685. doi:10.1038/nmeth0910-681 PubMed

53.

Barrett T, Wilhite SE, Ledoux P et al (2013) NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res 41:D991–D995. doi:10.1093/nar/gks1193 PubMedCentralPubMed

54.

Brazma A, Hingamp P, Quackenbush J et al (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365–371. doi:10.1038/ng1201-365 PubMed

55.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166–180PubMedCentralPubMed

56.

Bagger FO, Rapin N, Theilgaard-Mönch K et al (2013) HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis. Nucleic Acids Res 41:D1034–D1039. doi:10.1093/nar/gks1021 PubMedCentralPubMed

57.

Bagger FO, Rapin N, Theilgaard-Mönch K et al (2012) HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood 119:6394–6395. doi:10.1182/blood-2012-05-427310 PubMed

58.

Gry M, Rimini R, Strömberg S et al (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genom 10:365. doi:10.1186/1471-2164-10-365

59.

Uhlen M, Oksvold P, Fagerberg L et al (2010) Towards a knowledge-based human protein atlas. Nat Biotechnol 28:1248–1250. doi:10.1038/nbt1210-1248 PubMed

60.

Fernández-Suárez XM, Galperin MY (2013) The 2013 nucleic acids research database issue and the online molecular biology database collection. Nucleic Acids Res 41:D1–D7. doi:10.1093/nar/gks1297 PubMedCentralPubMed

61.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13:15PubMedCentralPubMed

62.

Almeida LG, Sakabe NJ, deOliveira AR et al (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37:D816–D819. doi:10.1093/nar/gkn673 PubMedCentralPubMed

63.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMed

64.

Allred DC, Clark GM, Molina R et al (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979PubMed

65.

Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMed

66.

Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285–4289PubMedCentralPubMed

67.

Rustici G, Kolesnikov N, Brandizi M et al (2013) ArrayExpress update—trends in database growth and links to data analysis tools. Nucleic Acids Res 41:D987–D990. doi:10.1093/nar/gks1174 PubMedCentralPubMed

68.

Amberger J, Bocchini CA, Scott AF, Hamosh A (2009) McKusick’s online Mendelian inheritance in man (OMIM). Nucleic Acids Res 37:D793–D796. doi:10.1093/nar/gkn665 PubMedCentralPubMed

69.

Flicek P, Ahmed I, Amode MR et al (2013) Ensembl 2013. Nucleic Acids Res 41:D48–D55. doi:10.1093/nar/gks1236 PubMedCentralPubMed

70.

Safran M, Dalah I, Alexander J et al (2010) GeneCards version 3: the human gene integrator. database (Oxford) baq020. doi: 10.1093/database/baq020

71.

Benson DA, Cavanaugh M, Clark K et al (2013) GenBank. Nucleic Acids Res 41:D36–D42. doi:10.1093/nar/gks1195 PubMedCentralPubMed

72.

The UniProt Consortium (2013) Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 41:D43–D47. doi:10.1093/nar/gks1068 PubMedCentral

73.

Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39:D945–D950. doi:10.1093/nar/gkq929 PubMedCentralPubMed

74.

Holzhütter HG, Kloetzel PM (2000) A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys J 79:1196–1205. doi:10.1016/S0006-3495(00)76374-0 PubMedCentralPubMed

75.

Kuttler C, Nussbaum AK, Dick TP et al (2000) An algorithm for the prediction of proteasomal cleavages. J Mol Biol 298:417–429. doi:10.1006/jmbi.2000.3683 PubMed

76.

Keşmir C, Nussbaum AK, Schild H et al (2002) Prediction of proteasome cleavage motifs by neural networks. Protein Eng 15:287–296PubMed

77.

Peters B, Bulik S, Tampe R et al (2003) Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171:1741–1749PubMed

78.

Zhang GL, Petrovsky N, Kwoh CK et al (2006) PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing. Immunome Res 2:3. doi:10.1186/1745-7580-2-3 PubMedCentralPubMed

79.

Bhasin M, Lata S, Raghava GPS (2007) TAPPred prediction of TAP-binding peptides in antigens. Methods Mol Biol 409:381–386. doi:10.1007/978-1-60327-118-9_28 PubMed

80.

Saxová P, Buus S, Brunak S, Keşmir C (2003) Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol 15:781–787PubMed

81.

Zhang GL, Ansari HR, Bradley P et al (2011) Machine learning competition in immunology—prediction of HLA class I binding peptides. J Immunol Methods 374:1–4. doi:10.1016/j.jim.2011.09.010 PubMed

82.

Lin HH, Ray S, Tongchusak S et al (2008) Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol 9:8. doi:10.1186/1471-2172-9-8 PubMedCentralPubMed

83.

Lin HH, Zhang GL, Tongchusak S et al (2008) Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinform 9(Suppl 12):S22. doi:10.1186/1471-2105-9-S12-S22

84.

Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24:1397–1398. doi:10.1093/bioinformatics/btn128 PubMed

85.

Nielsen M, Lund O (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinform 10:296. doi:10.1186/1471-2105-10-296

86.

Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMed

87.

Schuler MM, Nastke M-D, Stevanovikć S (2007) SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 409:75–93PubMed

88.

Hu X, Mamitsuka H, Zhu S (2011) Ensemble approaches for improving HLA class I-peptide binding prediction. J Immunol Methods 374:47–52. doi:10.1016/j.jim.2010.09.007 PubMed

89.

Huang JC, Jojic N (2011) Modeling major histocompatibility complex binding by nonparametric averaging of multiple predictors and sequence encodings. J Immunol Methods 374:35–42. doi:10.1016/j.jim.2010.10.001 PubMed

90.

Nielsen M, Lundegaard C, Blicher T et al (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2:e796. doi:10.1371/journal.pone.0000796 PubMedCentralPubMed

91.

Larsen MV, Lundegaard C, Lamberth K et al (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform 8:424. doi:10.1186/1471-2105-8-424

92.

Frankild S, de Boer RJ, Lund O et al (2008) Amino acid similarity accounts for T cell cross-reactivity and for “holes” in the T cell repertoire. PLoS ONE 3:e1831. doi:10.1371/journal.pone.0001831 PubMedCentralPubMed

93.

Pierce BG, Weng Z (2013) A flexible docking approach for prediction of T cell receptor–peptide–MHC complexes. Protein Sci 22:35–46. doi:10.1002/pro.2181 PubMedCentralPubMed

94.

Tung C-W, Ziehm M, Kämper A et al (2011) POPISK: T-cell reactivity prediction using support vector machines and string kernels. BMC Bioinform 12:446. doi:10.1186/1471-2105-12-446

95.

Saethang T, Hirose O, Kimkong I et al (2013) PAAQD: predicting immunogenicity of MHC class I binding peptides using amino acid pairwise contact potentials and quantum topological molecular similarity descriptors. J Immunol Methods 387:293–302. doi:10.1016/j.jim.2012.09.016 PubMed

96.

Olsen LR, Zhang GL, Keskin DB et al (2011) Conservation analysis of dengue virus T-cell epitope-based vaccine candidates using peptide block entropy. Front Immunol 2:69. doi:10.3389/fimmu.2011.00069 PubMedCentralPubMed

97.

Rongcun Y, Salazar-Onfray F, Charo J et al (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037–1044PubMed

98.

Reinhold B, Keskin DB, Reinherz EL (2010) Molecular detection of targeted major histocompatibility complex I-bound peptides using a probabilistic measure and nanospray MS(3) on a hybrid quadrupole-linear ion trap. Anal Chem 82:9090–9099. doi:10.1021/ac102387t PubMedCentralPubMed

99.

Andersen RS, Kvistborg P, Frøsig TM et al (2012) Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 7:891–902. doi:10.1038/nprot.2012.037 PubMed

100.

Erlich H (2012) HLA DNA typing: past, present, and future. Tissue Antigens 80:1–11. doi:10.1111/j.1399-0039.2012.01881.x PubMed

101.

Sette A, Sidney J (1998) HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 10:478–482PubMed

102.

Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201–212PubMed

103.

Robinson J, Halliwell JA, McWilliam H et al (2013) The IMGT/HLA database. Nucleic Acids Res 41:D1222–D1227. doi:10.1093/nar/gks949 PubMedCentralPubMed

104.

Helmberg W, Dunivin R, Feolo M (2004) The sequencing-based typing tool of dbMHC: typing highly polymorphic gene sequences. Nucleic Acids Res 32:W173–W175. doi:10.1093/nar/gkh424 PubMedCentralPubMed

105.

Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39:D913–D919. doi:10.1093/nar/gkq1128 PubMedCentralPubMed

106.

Helmberg W (2012) Bioinformatic databases and resources in the public domain to aid HLA research. Tissue Antigens 80:295–304. doi:10.1111/tan.12000 PubMed

107.

Hildesheim A, Apple RJ, Chen C-J et al (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 94:1780–1789PubMed

108.

Wang C, Krishnakumar S, Wilhelmy J et al (2012) High-throughput, high-fidelity HLA genotyping with deep sequencing. Proc Natl Acad Sci USA 109:8676–8681. doi:10.1073/pnas.1206614109 PubMedCentralPubMed

109.

Boegel S, Löwer M, Schäfer M et al (2013) HLA typing from RNA-Seq sequence reads. Genome Med 4:102. doi:10.1186/gm403

110.

Zhang GL, Keskin DB, Reinherz EL, Brusic V (2011) A cDNA microarray for rapid and economical identification of HLA profiles of individuals. In: IEEE international conference on bioinformatics and biomedical work, pp 677–679

111.

Pabinger S, Dander A, Fischer M et al (2014) A survey of tools for variant analysis of next-generation genome sequencing data. Brief Bioinform 15:256–278. doi:10.1093/bib/bbs086 PubMedCentralPubMed

112.

Buggert M, Norström MM, Czarnecki C et al (2012) Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage. PLoS ONE 7:e39874. doi:10.1371/journal.pone.0039874 PubMedCentralPubMed

113.

Bui H-H, Sidney J, Dinh K et al (2006) Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinform 7:153. doi:10.1186/1471-2105-7-153

114.

Warren RL, Choe G, Freeman DJ et al (2012) Derivation of HLA types from shotgun sequence datasets. Genome Med 4:95. doi:10.1186/gm396 PubMedCentralPubMed

115.

Kim HJ, Pourmand N (2013) HLA haplotyping from RNA-seq data using hierarchical read weighting. PLoS ONE 8:e67885. doi:10.1371/journal.pone.0067885 PubMedCentralPubMed

116.

Lundegaard C, Lamberth K, Harndahl M et al (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36:W509–W512. doi:10.1093/nar/gkn202 PubMedCentralPubMed

117.

Thompson JD, Gibson TJ, Higgins DG (2002) Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinform Chapter 2:Unit 2.3. doi: 10.1002/0471250953.bi0203s00

118.

Katoh K, Standley DM (2013) MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. doi:10.1093/molbev/mst010 PubMedCentralPubMed

119.

Edgar RC (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinform 5:113. doi:10.1186/1471-2105-5-113

120.

Bui H-H, Sidney J, Li W et al (2007) Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinform 8:361. doi:10.1186/1471-2105-8-361

121.

Olsen LR, Kudahl UJ, Simon C et al (2013) BlockLogo: visualization of peptide and sequence motif conservation. J Immunol Methods 400–401:37–44. doi:10.1016/j.jim.2013.08.014 PubMed

122.

Kawashima I, Hudson SJ, Tsai V et al (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1–14PubMed

123.

Forbes SA, Bhamra G, Bamford S et al (2008) The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet Chapter 10:Unit 10.11. doi: 10.1002/0471142905.hg1011s57

124.

Firth HV, Richards SM, Bevan AP et al (2009) DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. Am J Hum Genet 84:524–533. doi:10.1016/j.ajhg.2009.03.010 PubMedCentralPubMed

125.

Magrane M (2011) UniProt knowledgebase: a hub of integrated protein data. Database (Oxford) bar009. doi: 10.1093/database/bar009

126.

Andersen MH, Becker JC, Thor Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4:399–409. doi:10.1038/nrd1717 PubMed

127.

Lee MJ, Ye AS, Gardino AK et al (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149:780–794. doi:10.1016/j.cell.2012.03.031 PubMedCentralPubMed

128.

Liu J, Ewald BA, Lynch DM et al (2006) Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol 80:11991–11997. doi:10.1128/JVI.01348-06 PubMedCentralPubMed

129.

Ranieri E, Kierstead LS, Zarour H et al (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Investig 29:121–125

130.

Henderson RA, Finn OJ (1996) Human tumor antigens are ready to fly. Adv Immunol 62:217–256PubMed

131.

Reid A, Vidal L, Shaw H, de Bono J (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43:481–489. doi:10.1016/j.ejca.2006.11.007 PubMed

132.

Franceschini A, Szklarczyk D, Frankild S et al (2013) STRING v9.1: protein–protein interaction networks, with increased coverage and integration. Nucleic Acids Res 41:D808–D815. doi:10.1093/nar/gks1094 PubMedCentralPubMed

133.

Kawaguchi Y, Kono K, Mimura K et al (2007) Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97:494–501. doi:10.1038/sj.bjc.6603885 PubMedCentralPubMed

134.

Gutierrez C, Schiff R (2011) HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:55–62. doi:10.1043/2010-0454-RAR.1 PubMedCentralPubMed

135.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550. doi:10.1073/pnas.0506580102 PubMedCentralPubMed

136.

Chatr-Aryamontri A, Breitkreutz B-J, Heinicke S et al (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41:D816–D823. doi:10.1093/nar/gks1158 PubMedCentralPubMed

137.

Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27–30PubMedCentralPubMed

138.

Croft D, O’Kelly G, Wu G et al (2011) Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39:D691–D697. doi:10.1093/nar/gkq1018 PubMedCentralPubMed

139.

Caoili SEC (2010) Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects. J Biomed Biotechnol 2010:910524. doi:10.1155/2010/910524 PubMedCentralPubMed

140.

Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157. doi:10.1038/nbt1137 PubMed

141.

Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733. doi:10.1056/NEJMoa1103849 PubMedCentralPubMed

142.

El-Manzalawy Y, Honavar V (2010) Recent advances in B-cell epitope prediction methods. Immunome Res 6(Suppl 2):S2. doi:10.1186/1745-7580-6-S2-S2 PubMedCentralPubMed

143.

Möller S, Croning MD, Apweiler R (2001) Evaluation of methods for the prediction of membrane spanning regions. Bioinformatics 17:646–653PubMed

144.

Gajewski TF (2011) Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol 38:236–242. doi:10.1053/j.seminoncol.2011.01.004 PubMedCentralPubMed

145.

Galon J, Franck P, Marincola FM et al (2012) Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 10:205. doi:10.1186/1479-5876-10-205 PubMedCentralPubMed

146.

Galon J, Pagès F, Marincola FM et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1. doi:10.1186/1479-5876-10-1 PubMedCentralPubMed

147.

Pagès F, Kirilovsky A, Mlecnik B et al (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944–5951. doi:10.1200/JCO.2008.19.6147 PubMed

Title: Bioinformatics for cancer immunotherapy target discovery
Authors: Lars Rønn Olsen
Benito Campos
Mike Stein Barnkob
Ole Winther
Vladimir Brusic
Mads Hald Andersen
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 12/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-014-1627-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma

Retraction Note to: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF

Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma

Inconsistencies and questionable reliability of the publication “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophages-activating, GcMAF” by Yamamoto et al

Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer